Highlights

  • Vitasora Health shares climbed 36.36% during the morning session on 18 May 2026 following a favourable operational update.
  • The company confirmed successful implementation of its proprietary vCare EMR platform from 1 April 2026.
  • April patient enrolments reached 469, nearly double the February and March monthly averages.
  • May enrolment trends indicate a monthly run-rate above 550 patients.
  • Vitasora expects annualised operating and SaaS savings of approximately US$1.7 million to US$1.8 million.
  • More than US$490,000 in receivables has been collected since quarter-end.
  • Management continues targeting Business-as-usual cashflow breakeven during H2 CY2026.

Vitasora Health Ltd (ASX:VHL) shares surged 36.36% to AUD 0.015 during the morning session on 18 May 2026 after the company released a favourable operational update highlighting accelerating patient enrolments, platform deployment progress and anticipated cost savings linked to its proprietary vCare system. Despite today’s rally, the stock remains down 62.5% over the past year.

The latest update appears to have improved investor sentiment after the company outlined progress on several operational milestones previously flagged in its March Quarterly Report. The announcement included details on the successful rollout of Vitasora’s vCare Electronic Medical Record (EMR) platform, increasing enrolment momentum, improving receivables collections and expectations for material operating efficiencies from the migration away from legacy software systems.

Vitasora Health operates in the connected healthcare and chronic disease management sector, focusing on remote patient monitoring (RPM) and chronic care management (CCM) solutions across the United States healthcare market. The company combines software platforms, clinical teams and monitoring technologies to support healthcare providers managing patients with long-term chronic conditions. Its operations also include wheezo®, an FDA-approved wheeze monitoring medical device integrated into respiratory care programs.

vCare Platform Rollout Marks Key Operational Milestone

A major focus of the company’s latest update was the successful implementation of its proprietary vCare EMR platform, which officially became operational across the CCM business from 1 April 2026.

According to Vitasora, the rollout was completed in line with management expectations and supports the company’s transition toward a unified operating platform designed to improve workflow scalability, patient onboarding efficiency, reimbursement management and workforce flexibility.

The company also confirmed completion of the RPM module within the vCare platform. Final operational testing is currently underway, with commercial launch targeted from 1 July 2026.

Management indicated that the timing of the RPM rollout aligns with client reimbursement cycles and is intended to reduce data migration risks while supporting continuity across healthcare programs.

The transition away from the legacy Ceras platform is expected to represent a notable operational shift for the company. Once fully implemented, Vitasora expects vCare to materially reduce software-related costs while improving workflow automation and reimbursement integrity across patient programs.

Cost Reduction Initiatives Expected to Improve Operating Leverage

One of the more closely watched aspects of the update involved the anticipated reduction in software platform expenses following the migration to vCare.

The company stated that software platform costs are expected to decline by more than 90%, falling from approximately US$7 per patient per month to less than US$1 per patient per month once the transition is fully completed from July 2026.

For every 10,000 active patients, Vitasora estimates this reduction could generate annualised SaaS savings of approximately US$720,000, equivalent to around AUD 1.05 million.

In addition to software savings, management expects further annualised operating efficiencies of around US$1 million through workflow automation, reduced dependence on third-party systems and improved workforce utilisation.

Combined, these initiatives are projected to deliver total annualised savings of approximately US$1.7 million to US$1.8 million, or around AUD 2.4 million to AUD 2.6 million.

The company believes these operational efficiencies may improve overall operating leverage and support progress toward monthly business-as-usual cashflow breakeven.

Patient Enrolment Momentum Accelerates

Another key driver behind today’s market reaction appears to be the acceleration in patient enrolment activity following the vCare rollout.

Vitasora revealed that a previously disclosed opportunity involving approximately 40,000 patients from existing contracted clients has now entered an active enrolment acceleration phase.

The company had deliberately moderated enrolments during the March quarter while platform optimisation and workflow refinements were being completed. Since implementation of vCare, however, onboarding activity has increased materially.

April 2026 enrolments reached 469 patients, representing almost double the average monthly enrolments recorded during February and March 2026.

Momentum has continued into May. Within the first seven billing days of the month, Vitasora had already completed 163 patient enrolments. Based on current trends, management estimates this implies a monthly run-rate exceeding 550 enrolments.

The projected May pace represents growth of more than 130% compared to the February and March monthly averages.

The company estimates that every additional 1,000 active patients enrolled into its programs could generate approximately US$70,000 to US$120,000 in monthly Revenue depending on reimbursement pathways and care mix.

Revenue Scaling Targets Remain in Focus

Vitasora also provided updated context around its revenue scaling targets and pathway toward profitability.

Management stated that average Fee-for-Service revenue currently sits at approximately US$85 per patient per month.

Based on company estimates, a base of approximately 6,500 billed Fee-for-Service patients could support monthly Fee-for-Service revenue of around US$550,000.

When combined with existing UPEC call centre services and Transitional Care Management (TCM) and Per-Member-Per-Month (PMPM) revenue streams, the company estimates this could translate into a broader monthly revenue run-rate of roughly US$650,000.

According to management, this level represents the forecast threshold for business-as-usual profitability.

Vitasora’s current billed Fee-for-Service patient base stands at approximately 2,800 patients.

The company said current enrolment momentum, combined with operating efficiencies and expansion opportunities within RPM programs, continues to support management’s focus on achieving monthly business-as-usual profitability during the second half of calendar year 2026.

Receivables Collections and Debtor Metrics Improve

Beyond enrolment growth and platform development, the update also highlighted progress in cash collections and receivables management.

Vitasora disclosed that of the US$990,000 Accounts Receivable balance reported at 31 March 2026, approximately US$490,000 had already been collected by mid-May.

The company also reported favourable movement in debtor ageing metrics.

Receivables outstanding for more than 60 days declined by around 30% compared to the March ageing profile, while receivables outstanding for more than 90 days were reduced by approximately 40%.

Management attributed the improvement to stronger collection performance, improving operational discipline and ongoing customer engagement efforts.

The company stated it remains confident in recovering the remaining receivables, although timing of collections may vary depending on customer payment cycles.

Management Commentary Signals Confidence in Platform Scalability

Chief Executive Officer Marjan Mikel described the implementation of vCare as a transformational milestone for the business.

Management indicated that operational initiatives outlined during the March quarterly update have now been executed and early enrolment trends are beginning to reflect increasing onboarding activity.

The company also noted that completion of the RPM module positions Vitasora to complete the transition from legacy systems while maintaining reimbursement continuity for clients and patients.

According to management, early enrolment trends reinforce confidence in the scalability of the platform and the Demand opportunity available within the company’s existing client base.

What This Means for Investors

Vitasora’s latest update delivered several operational developments that appear to have improved market sentiment toward the company, including accelerating enrolment growth, implementation of the vCare platform, anticipated operating savings and improving receivables collections.

Investors also appear to be responding to the company’s continued focus on progressing toward monthly business-as-usual cashflow breakeven during H2 CY2026.

While the company remains in an earlier-stage scaling phase and the share price is still significantly lower over the past 12 months, today’s announcement provided the market with updated operational metrics tied to patient growth, revenue potential and cost efficiency initiatives.

With the RPM module expected to launch commercially from July 2026 and enrolment activity continuing to accelerate, investors are likely to remain focused on execution against the company’s operational and revenue scaling targets over coming quarters.